Albemarle supplies Dr. Reddy’s
This article was originally published in The Tan Sheet
Executive SummaryAlbemarle Corp. signs on India-based Dr. Reddy's Laboratories as a non-exclusive distributor of its bulk ibuprofen active pharmaceutical ingredient and to sell and distribute the product within its global client base. Under the terms of the already-in-effect agreement, Baton Rouge, La.-based Albemarle will supply a "substantial quantity" of ibuprofen API for Dr. Reddy's generic ibuprofen tablets, Albemarle says...
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.